TLIS
Income statement / Annual
Last year (2023), Talis Biomedical Corporation's total revenue was $412,000.00,
a decrease of 88.72% from the previous year.
In 2023, Talis Biomedical Corporation's net income was -$62.01 M.
See Talis Biomedical Corporation,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
Operating Revenue |
$412,000.00 |
$3.65 M |
$0.00 |
$10.94 M |
$3.98 M |
$2.39 M |
Cost of Revenue |
$41,000.00
|
$8.39 M
|
$2.62 M
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$371,000.00
|
-$4.74 M
|
-$2.62 M
|
$10.94 M
|
$3.98 M
|
$2.39 M
|
Gross Profit Ratio |
0.9
|
-1.3
|
0
|
1
|
1
|
1
|
Research and Development Expenses |
$40.69 M
|
$70.83 M
|
$157.59 M
|
$89.02 M
|
$23.81 M
|
$18.39 M
|
General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$13.10 M
|
$6.86 M
|
$5.43 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$28.21 M
|
$40.73 M
|
$42.42 M
|
$13.10 M
|
$6.86 M
|
$5.43 M
|
Other Expenses |
-$1.72 M
|
-$1.16 M
|
-$8.19 M
|
-$10.94 M
|
-$3.98 M
|
$0.00
|
Operating Expenses |
$67.19 M
|
$110.40 M
|
$191.82 M
|
$91.18 M
|
$26.70 M
|
$21.43 M
|
Cost And Expenses |
$67.23 M
|
$118.79 M
|
$191.82 M
|
$91.18 M
|
$26.70 M
|
$21.43 M
|
Interest Income |
$0.00
|
$0.00
|
$0.00
|
$54,000.00
|
$42,000.00
|
$93,000.00
|
Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$770,000.00
|
$11.60 M
|
$2.62 M
|
$1.37 M
|
$726,000.00
|
$647,000.00
|
EBITDA |
-$66.05 M |
-$106.31 M |
-$191.82 M |
-$90.42 M |
-$25.97 M |
-$20.78 M |
EBITDA Ratio |
-160.3
|
-31.53
|
0
|
-8.27
|
-6.53
|
-8.7
|
Operating Income Ratio |
-162.17
|
-31.53
|
0
|
-8.34
|
-6.71
|
-8.97
|
Total Other Income/Expenses Net |
$4.81 M
|
$2.13 M
|
-$220,000.00
|
$54,000.00
|
-$775,000.00
|
$93,000.00
|
Income Before Tax |
-$62.01 M
|
-$113.01 M
|
-$192.04 M
|
-$91.13 M
|
-$27.47 M
|
-$21.34 M
|
Income Before Tax Ratio |
-150.5
|
-30.95
|
0
|
-8.33
|
-6.91
|
-8.93
|
Income Tax Expense |
$0.00
|
-$2.13 M
|
-$1.58 M
|
-$54,000.00
|
-$42,000.00
|
$93,000.00
|
Net Income |
-$62.01 M
|
-$110.89 M
|
-$190.46 M
|
-$91.08 M
|
-$27.43 M
|
-$21.34 M
|
Net Income Ratio |
-150.5
|
-30.36
|
0
|
-8.33
|
-6.9
|
-8.93
|
EPS |
-34.12 |
-62.45 |
-126.13 |
-314.06 |
-182.88 |
-141.85 |
EPS Diluted |
-34.12 |
-62.45 |
-126.13 |
-314.06 |
-182.88 |
-141.85 |
Weighted Average Shares Out |
$1.82 M
|
$1.78 M
|
$1.51 M
|
$290,000.00
|
$150,000.00
|
$150,420.00
|
Weighted Average Shares Out Diluted |
$1.82 M
|
$1.78 M
|
$1.51 M
|
$290,000.00
|
$150,000.00
|
$150,420.00
|
Link |
|
|
|
|
|
|